A total of 9% of placebo recipients contracted COVID-19 from a household member, compared with 2.9% of ensitrelvir recipients ...

The conical capsule landed with the assistance of a parachute and was quickly recovered. The spacecraft carried a ...

Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

Scientists have found that an oral antiviral drug successfully prevents monkeys from dying after an Ebola infection, an advance that may prevent future outbreaks of the deadly virus. The Ebola virus ...

New research this month shows that the experimental antiviral obeldesivir prevented up to 100% of deaths in monkeys infected ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

Glioblastoma is a deadly brain cancer that resists most treatments,triggering the body’s antiviral response makes ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that ...